Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged between 18 and 80 years~* Patients admitted to an ICU with a need for mechanical ventilation for more than 48 hours at visit 0~* At high risk for acquiring infection against P. aeruginosa at visit 0.~* Patients who, as determined by the investigator, have a high probability of survival for at least 48 hours.~* In females, either childbearing potential terminated by surgery or 1 year post menopausal, or a negative pregnancy test and the willingness of practicing a reliable methods of contraception~* Written informed consent or waiver according to the national regulations~Exclusion Criteria:~* Known use of any other investigational or non-registered drug within 30 days prior to IC43 vaccination at Visit 0~* Low severity of illness defined by an acute physiology score \< 8 at visit 0~* Patients \< 6 months post organ transplantation~* Severe thrombocytopenia or other coagulopathy which in the opinion of the investigator makes the patient unsuitable for intramuscular injection~* Pregnancy, lactation~* Persons who have been committed involuntarily to an institution, e.g. mental health facility or prison, will not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IC43 100 mcg (Type: ACTIVE_COMPARATOR): IC43 100 mcg with Aluminum hydroxide
- IC43 200 mcg (Type: ACTIVE_COMPARATOR): IC43 200 mcg with Aluminum hydroxide
- IC43 100 mcg w/o (Type: ACTIVE_COMPARATOR): IC43 100 mcg without Aluminum hydroxide
- Placebo (Type: PLACEBO_COMPARATOR): phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).